Abstract
Transcranial direct current stimulation (tDCS) has been used to noninvasively reduce epileptic activity in focal epilepsy. In this proof-of-principle N-of-1 trial in a patient with drug-resistant focal epilepsy, we propose distributed constrained maximum intensity (D-CMI) for individually targeted and optimized multi-channel (mc-) tDCS to reduce epileptic activity. Combined electro- and magnetoencephalography (EMEG) source analysis in a realistic calibrated head model defines location and orientation of the target epileptogenic source. Converging evidence for this determination is achieved by retrospective identification of a cortical malformation in magnetic resonance imaging and by successful EMEG-guided invasive EEG. We applied D-CMI in a double-blind, sham-controlled stimulation experiment. In two stimulation weeks, either D-CMI or sham stimulation with 4 mA injection current were applied twice every week-day for 20 min each, with a 20 min pause in between. EEG was recorded 1 h before and after stimulation. For D-CMI, we find a highly significant reduction in IED frequency (p < 0.0001) marked by three experts of on average 37% to 81% over the five days of stimulation (mean ± SD: 58% ± 19%), while this is not the case for sham. The proposed procedure was well-tolerated and parameterizes a group clinical trial (Study registration number: DRKS00029384).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00029384
Funding Statement
This work was supported by the Bundesministerium fuer Gesundheit (BMG) as project ZMI1-2521FSB006, under the frame of ERA PerMed as project ERAPERMED2020-227 PerEpi, by the German Research Foundation (DFG) through projects WO1425/7-1 and RA2062/1-1, by EU project ChildBrain (Marie Curie innovative training network, grant no. 641652), by DAAD project 57663920 and by the Onassis Scholarship Foundation. We acknowledge support from the Open Access Publication Fund of the University of Muenster.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the institution's ethical review boards (Ethik Kommission der Aerztekammer Westfalen-Lippe und der Westfaelischen Wilhelms-Universitaet Muenster, 25.05.2021, Ref. No. 2021-290-f-S; Ethik-Kommission der Friedrich-Alexander-Universitaet Erlangen-Nuernberg, 20.02.2018, Ref. No. 4453B). The patient gave written informed consent for her data to be used in anonymized form for scientific publications.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
